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Objective To compare vaginal repair augmented by mesh with
traditional colporrhaphy for the treatment of pelvic organ prolapse.
Design Prospective randomised controlled trial.
Setting Tertiary teaching hospital.
Population One hundred and thirty-nine women with stage ‡2
prolapse according to the pelvic organ prolapse quantiﬁcation
(POP-Q) system requiring both anterior and posterior
compartment repair.
Methods Subjects were randomised to anterior and posterior
vaginal repair with mesh augmentation (mesh group, n = 69) or
traditional anterior and posterior colporrhaphy (no mesh group,
n = 70).
Main outcome measures The primary outcome was the absence
of POP-Q stage ‡2 prolapse at 12 months. Secondary outcomes
were symptoms, quality-of-life outcomes and satisfaction with
surgery. Complications were also reported.
Results For subjects attending the 12-month review, success in
the mesh group was 81.0% (51 of 63 subjects) compared with
65.6% (40/61) in the no mesh group and was not signiﬁcantly
different (P-value = 0.07). A high level of satisfaction with
surgery and improvements in symptoms and quality-of-life data
were observed at 12 months compared to baseline in both
groups, but there was no signiﬁcant difference in these outcomes
between the two groups. Vaginal mesh exposure occurred in
four women in the mesh group (5.6%). De novo dyspareunia
was reported by ﬁve of 30 (16.7%) sexually active women in the
mesh group and ﬁve of 33 (15.2%) in the no mesh group at
12 months.
Conclusion In this study, vaginal surgery augmented by mesh did
not result in signiﬁcantly less recurrent prolapse than traditional
colporrhaphy 12 months following surgery.
Keywords Colporrhaphy, mesh, pelvic organ prolapse, randomised
controlled trial.
Please cite this paper as: Carey M, Higgs P, Goh J, Lim J, Leong A, Krause H, Cornish A. Vaginal repair with mesh versus colporrhaphy for prolapse: a
randomised controlled trial. BJOG 2009;116:1380–1386.
Introduction
In the United States, 200 000 women undergo surgery annu-
ally for pelvic organ prolapse.
1,2 Combined anterior and pos-
terior colporrhaphy was performed on 35.2% women
undergoing prolapse surgery in 2003 and was the most com-
mon operation for this condition.
2 A lifetime risk of 11.1%
for surgery to treat pelvic organ prolapse or urinary inconti-
nence or both was reported by a study from a United States
health maintenance organisation.
3 Within 4 years of the
primary surgical procedure, further surgery for recurrent
prolapse and/or incontinence was required in 29.2%.
3
Dissatisfaction with traditional colporrhaphy for pelvic
organ prolapse has resulted in increased use of mesh to
augment vaginal repair procedures to obtain higher suc-
cess rates. However, the use of mesh during vaginal repair
procedures is controversial. Uncontrolled studies have
reported signiﬁcant problems (e.g. dyspareunia and mesh
exposure) with the use of mesh during vaginal prolapse
surgery.
4,5 By contrast, there is wide acceptance of mesh
use for prolapse with the abdominal sacral colpopexy
procedure.
6–8
This study was designed to evaluate whether vaginal sur-
gery with mesh augmentation would reduce the rate of
recurrent prolapse at 12 months when compared with tra-
ditional colporrhaphy. We also evaluated complications,
symptoms, quality-of-life outcomes and patient satisfaction
with surgery.
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Women recommended vaginal surgery for anterior and pos-
terior vaginal wall prolapse with stage 2 or more prolapse
according to the pelvic-organ-prolapse quantiﬁcation
(POP-Q) system were invited to participate in this study.
9
Women requiring only anterior or posterior compartment
repair or with prolapse of the vaginal vault or cervix beyond
the hymen or, in the opinion of the assessing surgeon,
required abdominal prolapse surgery with mesh (e.g. open or
laparoscopic sacral colpopexy) were excluded from the study.
Women with contraindications for mesh usage, such as prior
pelvic radiotherapy, pelvic sepsis, planned future pregnancy
or immunocompromised were ineligible for the study. Insti-
tutional research and ethics committee approval for this
study was obtained. All eligible women who agreed to partic-
ipate in this study and provided written informed consent
were enrolled between February 2003 and August 2005.
A sample size of 128 women (64 in each group) was
required to achieve a signiﬁcance level of 0.05 with a power
of 0.8. This was based on the assumptions of 71% cure for
traditional colporrhaphy and 93% for vaginal repair with
mesh augmentation and a 15% loss to follow-up rate.
3,10
Randomisation was computer generated and assignment
was revealed prior to surgery. Subjects and surgeons were
not blinded to the intervention.
Patients were assessed clinically and the prolapse staged
using the POP-Q quantiﬁcation system. Multichannel uro-
dynamics was performed on subjects with urinary inconti-
nence prior to surgery. All subjects completed validated
questionnaires prior to surgery and at 6 and 12 months
following surgery. The questionnaires were the Prolapse
Symptom Inventory and Quality of Life questionnaire
(PSI-QOL), Short-form Urogenital Distress inventory
(SUDI), Short-form Incontinence Impact questionnaire
(SIIQ) and Cleveland Clinic Continence score (CCCS).
11–13
The subjects also completed a visual analogue scale (VAS;
0-100 where 100 represented being completely satisﬁed and
0 completely dissatisﬁed) of their satisfaction with surgery
at 6 and 12 months following surgery.
The primary outcome was objective success of surgery as
deﬁned by the absence of POP-Q stage 2 or more prolapse
(i.e. no prolapse at or below a point 1 cm above the hymen
at any vaginal site) 12 months following surgery. Secondary
outcomes were symptoms, quality-of-life outcomes and
patient satisfaction with surgery at 6 and 12 months. Com-
plications of surgery were also reported.
If a tension-free vaginal tape (TVT) or trans-obturator
tape was required, this was undertaken at the start of sur-
gery. A vaginal hysterectomy was then performed for
women requiring this procedure. The vagina repair proce-
dure was then performed. A perineal repair was performed
as required.
Patients randomised to the no mesh group underwent
standard anterior and posterior colporrhaphy. Plication of
the pre-vesical and pre-rectal tissue with 2/0 polydioxanone
sutures was performed. Excess vaginal epithelium was
excised as required and closed with a continuous locking
suture.
When mesh was used in the anterior vaginal repair, a
full thickness midline epithelial incision was made. The
vaginal epithelium was mobilised off the underlying
pre-vesical tissue. Dissection continued towards each arcus
tendineus fascae pelvis (ATFP). The inner aspect of the
pubic bone was palpated at the level of the mid-vagina and
lateral dissection was then continued through the ATFP
with ﬁne scissors using a ‘push-spread’ technique for
approximately 3 cm. Only the central area of the pre-
vesical fascia was repaired with 2/0 Monocryl (Ethicon,
Somerville, NJ, USA). This avoided narrowing the pre-
vesical space. The mesh (Gynemesh PS; Ethicon) was
soaked in an antibiotic solution prior to placement and
liberal wound irrigation with saline was performed during
surgery. A cross-shaped piece of mesh was cut and placed
over the pre-vesical tissue with the extension arms placed
into each paravaginal space (Figure 1). The mesh extension
arms abutted the inner aspect of the pubic bone on each
side. Excess vaginal epithelium was trimmed as required
and closed with a nonlocking continuous everting mattress
suture.
When mesh was used to reinforce the posterior vaginal
repair, a full thickness midline epithelial incision was made.
The vaginal epithelium was dissected off the underlying
pre-rectal tissue. Dissection continued laterally on each side
to the levator ani muscles. At the apex, dissection continued
through the rectal pillars to each ischial spine and sacro-
spinous ligament. Only the central area of the pre-vesical
fascia was repaired with 2/0 Monocryl. This prevented
narrowing the pre-rectal space. A ‘Y’-shaped piece of mesh
was cut and placed over the pre-rectal tissue with the exten-
sion arms placed in the tunnels created by the dissection
onto the sacrospinous ligaments (Figure 2). The mesh
Figure 1. A cross-shaped mesh was used for the anterior vaginal
repair. The extension arms were placed into each paravaginal space.
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was not placed in the lower third of the posterior vaginal wall.
The vaginal epithelium was trimmed as required and closed
withanonlocking continuous everting mattress suture.
Sacrospinous ligament ﬁxation of the vaginal vault or
uterus as described by Carey and Slack was performed at
the discretion of the surgeon.
14 For seven subjects, laparo-
scopic suture sacral hysteropexy was performed as
described by Krause et al.
15
All patients received intra-operative antibiotics and
thromboprophylaxsis. For subjects assigned to the mesh
group, perioperative intravenous antibiotics were continued
for 48 hours followed by oral antibiotics for a further 5 days.
Follow-up examination was performed at 6 and
12 months. During the examination, the examiner
attempted to remain blinded to the surgical intervention
received by each subject. Patient satisfaction using a visual
analogue score (VAS) and validated symptom and quality-
of-life questionnaires (Prolapse Symptom Inventory &
QOL [PSI-QOL]) were administered at 6 and 12 months
postoperatively.
Fisher’s exact test was used for discrete outcomes.
Two-sample t-test was used for parametric continuous
data.
Results
We recruited 139 women into the study (Figure 3). Depar-
ture from study protocol occurred in seven women with
uterine prolapse who underwent laparoscopic suture sacral
hysteropexy (two in the mesh and ﬁve in the no mesh
group), two women who underwent a single compartment
posterior repair (one in the mesh and one in the no mesh
group) and one subject treated without mesh with a stage
4 uterine prolapse. In an attempt to replace these subjects,
a further 11 women were recruited into the study in addi-
tion to the 128 planned recruits. All 139 women remained
in the ﬁnal analysis based on an intention-to-treat analysis.
Therefore, for purposes of analysis, there were 69 women
in the mesh group and 70 women in the no mesh group.
There were no signiﬁcant differences in demographics
between the two groups (Table 1).
Of the 139 women recruited, 108 (58 in the mesh group
and 50 in the no mesh group) attended for the 6-month
follow up and 124 (63 in the mesh group and 61 in the no
mesh group) attended for the 12 month follow up. We
chose to report the 12-month results for the primary and
secondary outcomes.
A mid-urethral sling for stress incontinence was
performed in 49% of the mesh group and 33% of the no
mesh group. Twenty-seven percent of women in the mesh
group and 28% in the no mesh group had a vaginal
hysterectomy. Sacrospinous ﬁxation was performed in 58%
of the mesh group and 47% in the no mesh group.
Figure 2. A ‘Y’-shaped mesh was used for the posterior vaginal repair.
The extensions arms abutted each sacrospinous ligament.
Table 1. Demographics and preoperative details for mesh and no
mesh groups
Variable Mesh
(n = 69)
No mesh
(n = 70)
P-value
Age in years, mean (SD) 59.1 (±11.4) 57.6(±11.0) 0.42*
Parity, mean (SD) 3.24 (±1.59) 3.42 (±1.62) 0.51*
BMI (kg/m
2), mean (SD) 28.89 (±5.56) 28.66 (±5.04) 0.81*
No. subjects analysed
1 63 61
Hormone therapy 18.5% 15.7% 0.80**
No. subjects analysed
1 54 51
Prior Prolapse Surgery 13.6% 26.2% 0.08**
Prior Hysterectomy 31.9% 41.4% 0.29**
No. subjects analysed
1 22/69 29/70
Dyspareunia
5 32.4% 55.6% 0.06**
Proportion
1 11/35 20/34
*Two sample t-test.
**Fisher’s exact test.
Mesh allocation and 
surgery 
n = 69
No mesh allocation and 
surgery 
n = 70
12-month follow-up 
n = 63
12-month follow-up 
n = 61
Lost to follow-
up from baseline 
n = 9
Lost to follow-
up from baseline 
n = 6 
Enrolled, randomised and 
underwent surgery 
n = 139 
Figure 3. Study ﬂow chart.
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detailed in Table 2. For the primary outcome, we examined
varying assumptions about data from women lost to follow
up. Results are reported just for women returning for fol-
low up (i.e. assuming that data were missing at random);
assuming that women lost to follow up were treatment fail-
ures; and assuming that women lost to follow up were
treatment successes.
Recurrent prolapse occurred most commonly in the
anterior compartment. In the mesh group, no recurrence
was more than point 0 and in the no mesh group, no
recurrence was more than point +1 on POP-Q examina-
tion. Of those women with recurrences, one woman has
undergone a laparoscopic sacral colpopexy and another has
undergone a vaginal repair with mesh. Both subjects were
from the no mesh group.
The results of PSI-QOL, SUDI, SIIQ and CCCS question-
naires are detailed in Table 2. For all four questionnaires,
higher scores indicate worsening symptoms or impaired
quality of life. The changes in scores for each scale from
baseline to 12 months following surgery have been reported.
Therefore, a positive change indicates an increase in score
over time and a negative change indicates a decrease in score
over time. For all scales, a negative change in score was
observed from baseline to 12 month after surgery indicating
improved symptoms or quality of life.
Intra-operative complications included one bladder per-
foration and one bowel perforation in the no mesh group.
Both perforations were noted during the surgery and
repaired intra-operatively without postoperative sequeale.
One subject in the mesh group experienced signiﬁcant
intra-operative blood loss.
Postoperative complications included four cases (5.6%)
of vaginal mesh exposure in the mesh group. Three mesh
exposures were anterior and one was both anterior and
posterior. Only one patient who developed a mesh expo-
sure had a concomitant vaginal hysterectomy. Three of the
mesh exposures presented at the 6-week postoperative
review and one presented at 12 months. Three mesh expo-
sures were treated surgically by simple excision of the
exposed mesh and one case was managed conservatively.
There was one tape exposure from a TVT procedure in the
no mesh group.
Women were questioned regarding sexual activity and
dyspareunia preoperatively and at 6 and 12 months.
Eleven of 34 (32.4%) sexually active women in the mesh
Table 2. Primary and secondary outcomes at 12 months following surgery
Variable Mesh (n = 69) No mesh (n = 70) P-value
Objective success (POP-Q stage 0 or 1)
at 12 months of subjects returning for
follow up
51/63 (81.0%) 40/61 (65.6%) 0.07*
Objective success (POP-Q stage 0 or 1)
at 12 months assuming subjects lost to
follow up as failures
51/69 (73.9%) 40/70 (57.1%) 0.049*
Objective success (POP-Q stage 0 or 1)
at 12 months assuming subjects lost to
follow up as successes
57/69 (82.6%) 49/70 (70.0%) 0.11*
PSI-QOL, mean change from preoperative
to 12 months score** (SD)
)6.93 (±8.25) )7.77 (±7.43) 0.58***
No. subjects analysed 55 53
SUDI, mean change from preoperative
to 12 months score** (SD)
)20.4 (±29.5) )17.6 (±30.9) 0.62***
No. subjects analysed 59 57
SIIQ, mean change from preoperative to
12 months score** (SD)
)17.3 (±30.9) )15.0 (±33.2) 0.76***
No. subjects analysed 35 37
CCCS, mean change from preoperative
to 12 months score** (SD)
)1.00 (±4.20) )0.75 (±4.30) 0.78***
No. subjects analysed 50 44
Subjects reporting a VAS for satisfaction
with surgery of ‡80/100
45/59 (91.5%) 51/63 (81.0%) 0.12*
Awareness of prolapse 3/61 (4.9%) 7/62 (11.3%) 0.32*
*Fisher’s exact test.
**A negative change indicates a decrease in score over time and improved symptoms or impaired quality of life.
***Two sample t-test for independent means.
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described preoperative dyspareunia. This difference was
not signiﬁcant (P = 0.07). At the 6-month review, six of
25 (24.0%) in the mesh group and 11 of 27 (40.7%) in
the no mesh group reported dyspareunia (P = 0.25). At
12 months, 12 of 30 (40.0%) in the mesh group and 13
of 33 (39.4%) in the no mesh group reported dyspareunia
(P = 1). De novo dyspareunia was reported by ﬁve of
18 (27.8%) sexually active women without preoperative
dyspareunia in the mesh group and ﬁve of 12 (41.7%) in
the no mesh group at 12 months (P = 0.46). Dyspareunia
following surgery was considered to be because of vaginal
stenosis in three women in the mesh group and ﬁve
women in the no mesh group. Two women underwent
vaginoplasty for vaginal stenosis and both were from the
no mesh group.
Discussion
Our results failed to demonstrate that vaginal repair sur-
gery augmented by mesh was signiﬁcantly more successful
in terms of reduced recurrent prolapse than traditional
colporrhaphy 12 months following surgery. This ﬁnding
was based on analysis of only those women who returned
for the 12-month review. Alternative assumptions about
missing data suggested a signiﬁcantly higher success rate
for the primary outcome measure for the mesh group
when subjects not returning for review were assumed to be
treatment failures.
While designing the study, we chose a relatively homoge-
nous group of women requiring both anterior and poster-
ior vaginal repair surgery with limited apical prolapse. This
avoided the need for within group analysis and the prob-
lem of how to deal with women developing prolapse in the
nonrepaired compartment.
16 Departures from the study
protocol were included in the ﬁnal analysis on an inten-
tion-to-treat basis. However, the requirement for additional
surgery for stress urinary incontinence and vaginal vault
prolapse adds heterogeneity to the study population, and
this together with protocol departures and missing data,
undoubtedly effects the power of our study. Our failure to
detect a difference between these procedures does not mean
that such a difference could not exist.
Combined anterior and posterior colporrhaphy was
chosen as the comparator as this is the most common pro-
cedure performed for prolapse in the USA.
2 This operation
was performed on 35.2% of 199 698 women undergoing
prolapse surgery in the USA in 2003 compared to 17.0% of
women undergoing anterior and 16.4% undergoing poster-
ior colporrhaphy.
2 Four randomised controlled studies have
compared traditional colporrhaphy with vaginal repair with
synthetic or biological graft augmentation with conﬂicting
results. A recent study demonstrated that anterior col-
porrhaphy reinforced with mesh signiﬁcantly reduced
recurrent cystocele from 38.5 to 6.7% when compared with
traditional anterior colporrhaphy.
17 Another study reported
that vaginal repair augmented by polyglactin 910 absorb-
able mesh signiﬁcantly reduced recurrent cystocele from
43% in the no mesh group to 25% in the mesh group, but
there was no difference in the rate of recurrent rectocele
between the two groups.
18 A further study demonstrated
no signiﬁcant difference in cystocele recurrence rates when
three anterior repair techniques were compared, including
one group with polyglactin 910 mesh reinforcement.
19
Another study reported anterior colporrhaphy augmented
by solvent dehydrated fascia lata did not reduce recurrent
cystocele compared with traditional colporrhaphy.
20 Two
further studies have compared abdominal sacral colpopexy
with transvaginal sacrospinous colpopexy.
8,21 Both studies
reported a trend towards the abdominal sacral colpopexy
being associated with less recurrent prolapse and dyspareu-
nia than sacrospinous colpopexy. Both studies have been
widely interpreted as comparisons between abdominal and
vaginal surgery for prolapse. However, in both studies, the
subjects were randomised to prolapse surgery with mesh
(abdominal sacral colpopexy) and without mesh
(sacrospinous colpopexy) with less recurrent prolapse and
dyspareunia reported in the mesh group.
The impact of surgery on sexual function is difﬁcult to
quantify. On direct questioning, the rates of dyspareunia
were high in both groups preoperatively and at 6 and
12 months following surgery. These rates seemed to ﬂuctu-
ate with time. The high prevalence of dyspareunia is
consistent with other studies.
22,23 There was an improve-
ment in sexual function according to the PSI-QOL ques-
tionnaire in both groups following surgery. Interestingly,
some women who reported no sexual activity to the
medical staff reported sexual dysfunction because of pelvic
symptoms in the self-administered PSI-QOL questionnaire.
This may reﬂect a reluctance to discuss these issues with
the medical staff. We observed that de novo dyspareunia at
12 months following surgery was higher in the no mesh
group compared with the mesh group. This may be
explained by the different surgical techniques between
traditional colporrhaphy and mesh-augmented repair. With
colporrhaphy, the more lateral plication of the pre-vesical
and pre-rectal tissues may result in reduced vaginal
capacity compared with the mesh repair with plication of
only the central pre-vesical and pre-rectal tissues.
The prevalence of vaginal mesh exposure (5.6%) in the
mesh group is similar to rates reported for abdominal
sacral colpopexy. A comprehensive review of abdominal
sacral colpopexy by Nygaard et al. identiﬁed a 3.4% preva-
lence of mesh erosion.
6 A more recent study of 313 women
treated by abdominal sacral colpopexy reported a mesh
erosion rate of 5.4%.
24
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Our study showed no signiﬁcant reduction in recurrent
prolapse 12 months following anterior and posterior
vaginal repair with mesh augmentation compared with
standard anterior and posterior colporrhaphy. Given our
sample size and the number of patients failing to attend
follow up, conclusions regarding the primary outcome
were sensitive to assumptions made regarding those lost to
follow up. A larger study is required to more conclusively
assess the effectiveness and safety of mesh-augmented
vaginal repair surgery.
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